Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.03 USD
Change Today +0.0005 / 1.59%
Volume 233.1K
DNDNQ On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

dendreon corp (DNDNQ) Snapshot

Open
$0.03
Previous Close
$0.03
Day High
$0.03
Day Low
$0.03
52 Week High
07/8/14 - $2.49
52 Week Low
05/20/15 - $0.03
Market Cap
5.1M
Average Volume 10 Days
678.2K
EPS TTM
$-1.01
Shares Outstanding
158.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DENDREON CORP (DNDNQ)

dendreon corp (DNDNQ) Related Businessweek News

No Related Businessweek News Found

dendreon corp (DNDNQ) Details

Dendreon Corporation, a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. The company’s product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating various types of cancers. Its product candidates under research and development includes DN24-02, an investigational active cellular immunotherapy, which is in Phase II clinical trial for the treatment of patients with bladder, breast, ovarian, and other solid tumors expressing HER2/neu; carbonic anhydrase 9, an antigen expressed in renal cell carcinoma; carcinoembryonic antigen, an antigen expressed in colorectal and other cancers; and Transient Receptor Potential, sub-family M 8, a small molecule that has completed Phase I clinical trial to treat various types of cancers. Dendreon Corporation was founded in 1992 and is headquartered in Seattle, Washington. On November 10, 2014, Dendreon Corporation filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.

710 Employees
Last Reported Date: 11/10/14
Founded in 1992

dendreon corp (DNDNQ) Top Compensated Officers

Chief Financial Officer and Treasurer
Total Annual Compensation: $354.1K
Compensation as of Fiscal Year 2013.

dendreon corp (DNDNQ) Key Developments

Dendreon Corp. Announces Management Changes

Dendreon Corporation and its wholly owned subsidiaries, Dendreon Holdings, LLC, Dendreon Distribution, LLC and Dendreon Manufacturing, LLC (the Company, the Debtors) and Valeant Pharmaceuticals International Inc. and Drone Acquisition Sub Inc., a wholly-owned direct subsidiary of Valeant, entered into a second amended and restated acquisition agreement pursuant to which the Purchaser agreed to acquire substantially all of the assets and certain liabilities of the Debtors for an aggregate purchase price of $495 million. On February 23, 2015, the Company completed the Sale Transaction. Pursuant to the terms of the Acquisition Agreement, prior to the closing of the Sale Transaction, Valeant or one of its affiliates was required to extend offers of employment to each employee of the Company. On February 23, 2015, in connection with the closing of the Sale Transaction, Gregory R. Cox, Executive Vice President, Chief Financial Officer and Treasurer, ceased to be employed by the Company and became an employee of Valeant or one of its affiliates. As a result of the completion of the Sale Transaction, on February 27, 2015, the Debtors terminated without cause the employment of W. Thomas Amick, Chief Executive Officer and President of the Company, effective immediately. As of such date, Mr. Amick is no longer a director of the Company. On February 26, 2015, Mr. Cox accepted new employment with the Company as Chief Financial Officer and Treasurer, and Robert L. Crotty accepted new employment with the Company as General Counsel and Secretary. Mr. Crotty also became President of the Company, effective upon such position becoming vacant at the Company following the departure of Mr. Amick. Mr. Cox, previously served as Executive Vice President, Chief Financial Officer and Treasurer of the Company. Prior to joining Dendreon, Mr. Cox served as Vice President and Treasurer at Corixa Corporation. Mr. Crotty, previously served as Executive Vice President, General Counsel and Secretary of the Company. Previously, Mr. Crotty served as Senior Director, Senior Counsel and Assistant Secretary at NPS Pharmaceuticals Inc. from February 2009 until March 2012.

Dendreon Corp. Reports Revenue Results for the Fourth Quarter and Year Ended December 31, 2014

Dendreon Corp. reported revenue results for the fourth quarter and year ended December 31, 2014. The company finished 2014 strong with a net product revenue for the year ended December 31, 2014 of $303.8 million compared to $283.7 million for the year ended December 31, 2013. Net product revenue for the fourth quarter ended December 31, 2014 was $79.8 million compared to $74.8 million for the fourth quarter ended December 31, 2013.

Nasdaq Files Form 25-NSE With Securities And Exchange Commission To Delist Securities Of Dendreon Corporation

As previously announced, on November 10, 2014, Dendreon Corporation and its wholly owned subsidiaries, Dendreon Holdings, LLC, Dendreon Distribution, LLC and Dendreon Manufacturing, LLC filed voluntary petitions for relief (Chapter 11 Cases) under Chapter 11 of Title 11 of the United States Code (Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware. On November 10, 2014, as previously disclosed, the company received a Staff Delisting Determination letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the Staff had determined that the company’s securities would be delisted from Nasdaq unless the company requested an appeal of such determination. As the company did not request a hearing before the Nasdaq Hearings Panel by November 17, 2014, trading of the company’s securities on Nasdaq was suspended at the opening of business on November 19, 2014. On December 11, 2014, Nasdaq filed a Form 25-NSE with the Securities and Exchange Commission, which will remove the company’s securities from listing and registration on Nasdaq, effective at the opening of the trading session on December 22, 2014. Since its suspension from Nasdaq, the company’s common stock has been quoted on the OTC Pink Marketplace.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DNDNQ:US $0.03 USD +0.0005

DNDNQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DNDNQ.
View Industry Companies
 

Industry Analysis

DNDNQ

Industry Average

Valuation DNDNQ Industry Range
No financial data is available for DNDNQ.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DENDREON CORP, please visit www.dendreon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.